# Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

> **NCT06905483** · PHASE4 · COMPLETED · sponsor: **Thammasat University** · enrollment: 22 (actual)

## Conditions studied

- COPD
- Chronic Obstructive Pulmonary Disease (COPD)
- Small Airway Disease
- Triple Therapy
- Lung Function

## Interventions

- **DRUG:** Budesonide/Glycopyrronium/Formoterol (BGF)
- **DRUG:** Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

## Key facts

- **NCT ID:** NCT06905483
- **Lead sponsor:** Thammasat University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-01-28
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905483, "Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06905483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*